Current Evidence and Future Directions of Neoadjuvant Treatments for Clear Cell Renal Cell Carcinoma
By
Thomas McMaster
Niall McVeigh
David C. Chen
Abdullah Al-Khanaty
Kieran Sandhu
Jonathon Carll
Dixon T. Woon
Declan G. Murphy
Nathan Lawrentschuck
Lewis Au
Muhammad Ali
Shankar Siva
Marlon Perera
July 17, 2026
Clinical Scorecard: Current Evidence and Future Directions of Neoadjuvant Treatments for Clear Cell Renal Cell Carcinoma
At a Glance
Category Detail
Condition Clear Cell Renal Cell Carcinoma (ccRCC) Key Mechanisms Targeted therapies and immune checkpoint inhibitors modulate tumorigenesis and the tumor microenvironment. Target Population Patients with locally advanced or metastatic clear cell renal cell carcinoma. Care Setting Oncology and surgical settings for renal cell carcinoma management.
Key Highlights
Neoadjuvant therapy may induce tumor cytoreduction and downstaging. Combination strategies of ICI and TKI have improved survival in metastatic RCC. Neoadjuvant systemic therapy can enhance immune response and reduce surgical complexity. Guideline-Based Recommendations
Diagnosis
Utilize modern imaging techniques for early detection of renal tumors. Management
Consider neoadjuvant systemic therapy for high-risk and locally advanced RCC. Monitoring & Follow-up
Assess Objective Response Rate (ORR) and pathological response rate to evaluate treatment efficacy. Risks
Potential for metastatic recurrence despite curative-intent surgery. Patient & Prescribing Data
Patients diagnosed with clear cell renal cell carcinoma, particularly those with locally advanced disease.
Neoadjuvant therapies may improve surgical outcomes and long-term oncological results.
Clinical Best Practices
Incorporate neoadjuvant therapy in treatment plans for complex cases involving tumor thrombus. Utilize standardized assessment criteria for evaluating treatment response. Related Resources & Content
